Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fostamatinib Disodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,619Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Paragraph IV Patent Litigation for Fostamatinib Disodium
    FDA Confirms Paragraph IV Patent Litigation for Fostamatinib Disodium

    13 Jun 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-fostamatinib-disodium-1655270191.pdf

    FDA
    13 Jun 2022
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
    FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.

    13 Jun 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-aprepitant-azilsartan-bupivacaine-cladribine-elrombopag-fosnetupitant-fostamatinib-ivacaftor-and-sodium-thiosulfate-1655270821.pdf

    FDA
    13 Jun 2022
    Share Share
    Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
    Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

    29 Jun 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fostamatinib-selected-for-nih-activ-4-covid-19-clinical-trial-301321604.html

    PR NEWSWIRE
    29 Jun 2021
    Share Share
    Rigel’s fostamatinib meets primary endpoint in Covid-19 clinical trial
    Rigel’s fostamatinib meets primary endpoint in Covid-19 clinical trial

    14 Apr 2021

    // CLINCALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/rigel-fostamatinib-primary-endpoint/

    CLINCALTRIALSARENA
    14 Apr 2021
    Share Share
    Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety
    Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety

    13 Apr 2021

    // RIGEL

    https://www.rigel.com/investors/news-events/press-releases/detail/312/positive-topline-data-shows-fostamatinib-meets-primary

    RIGEL
    13 Apr 2021
    Share Share
    Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial
    Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial

    12 Mar 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/rigel-concludes-enrolment-trial/

    CLINICALTRIALSARENA
    12 Mar 2021
    Share Share